Advanced Therapies for Pediatric Obesity (ATPO) Conference
***Due to COVID19, the ATPO conference for 2020 is canceled. The new dates are Thursday, September 30 & October 1st, 2021***
The updated conference details will be posted shortly.
The Center for Pediatric Obesity Medicine (CPOM) sponsors the annual Advanced Therapies for Pediatric Obesity (ATPO) Conference.
Each year 20 health professional gather to focus on the use of pharmacotherapy for pediatric obesity safely while identifying biological targets of obesity treatments and mechanisms of action and outcomes of currently FDA-approved and off-label medications for the treatment of obesity in adults and youth.
ACTIVITY PURPOSE/STATEMENT OF NEED
Youth with severe obesity are often unable to lose a clinically-meaningful amount of weight with lifestyle modification alone. Pharmacological therapies are emerging as a recognized adjunctive strategy to address this otherwise recalcitrant disease, yet no guidelines currently exist for the responsible clinical use of obesity pharmacotherapy in the pediatric patient.
Health care providers, researchers, and others interested in the clinical management of pediatric obesity.
Case studies, lectures, and group discussion.
Following completion of this activity, learners should be better able to:
- Utilize pharmacotherapy for pediatric obesity in a safe and responsible fashion
- Identify biological targets of obesity treatments
- Identify the mechanisms of action and outcomes of currently FDA-approved and off-label medications for the treatment of obesity in adults and youth
In support of improving patient care, University of Minnesota, Interprofessional Continuing Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation Statements
American Medical Association (AMA)
The University of Minnesota, Interprofessional Continuing Education designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™.